ReviewMarine drugs2020
Astaxanthin as a Putative Geroprotector: Molecular Basis and Focus on Brain Aging.
Review in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 57 citations in OpenAlex.
- Pilot Randomized Controlled Trial of Krill Oil Supplementation for Chronic Musculoskeletal Pain in Older Adults.The Journal of nutrition · 2026Trial
- Krill Oil for Pain in Elders: protocol for a pilot, double-blind, randomised controlled trial to evaluate the efficacy of 4 g/d krill oil supplementation for chronic musculoskeletal pain and mobility limitations in older adults.The British journal of nutrition · 2026Article
- Exploring the Multifunctional Benefits of Astaxanthin in Aging, Oxidative Stress, Immune Dysfunction, Gut and Skin Health.Antioxidants (Basel, Switzerland) · 2026Review
- A collagen amino acid composition supplementation reduces biological age in humans and increases health and lifespan in vivo.npj aging · 2025Article
- Phytochemicals encouraging neurotrophic pathways: brain-derived neurotrophic factors as molecular targets in depression.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Tapping the microalgal potential: genetic precision and stress-induction for enhanced astaxanthin and biofuel production.Biotechnology for biofuels and bioproducts · 2025Review
- Sex as a major determinant of pro-longevity drug efficacy: a review of two decades of the NIA Interventions Testing Program.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Review
- Effects of 4-week astaxanthin supplementation on athletic performance and body composition in young male taekwondo athletes: a randomized, double-blind, placebo-controlled trial.Frontiers in nutrition · 2025Article
- Testing the amount of nicotinamide mononucleotide and urolithin A as compared to the label claim.GeroScience · 2024Article
- Protective effects of astaxanthin on particulate matter 2.5‑induced senescence in HaCaT keratinocytes via maintenance of redox homeostasis.Experimental and therapeutic medicine · 2024Article
- Review
- Article
- Dietary Astaxanthin: A Promising Antioxidant and Anti-Inflammatory Agent for Brain Aging and Adult Neurogenesis.Marine drugs · 2023Review
- Endoplasmic Reticulum Stress and Its Impact on Adipogenesis: Molecular Mechanisms Implicated.Nutrients · 2023Review
- Cell Survival, Death, and Proliferation in Senescent and Cancer Cells: the Role of (Poly)phenols.Advances in nutrition (Bethesda, Md.) · 2023Review
- Astaxanthin as a King of Ketocarotenoids: Structure, Synthesis, Accumulation, Bioavailability and Antioxidant Properties.Marine drugs · 2023Review
- Antioxidant and Anti-Inflammatory Effects of Carotenoids in Mood Disorders: An Overview.Antioxidants (Basel, Switzerland) · 2023Review
- The Role of Astaxanthin as a Nutraceutical in Health and Age-Related Conditions.Molecules (Basel, Switzerland) · 2022Review
- Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Immunomodulatory and Antiaging Mechanisms of Resveratrol, Rapamycin, and Metformin: Focus on mTOR and AMPK Signaling Networks.Pharmaceuticals (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
In recent years, the scientific interest in natural compounds with geroprotective activities has grown exponentially. Among the various naturally derived molecules, astaxanthin (ASX) represents a highly promising candidate geroprotector. By virtue of the central polyene chain, ASX acts as a scavenger of free radicals in the internal membrane layer and simultaneously controls oxidation on the membrane surface. Moreover, several studies have highlighted ASX's ability to modulate numerous biological mechanisms at the cellular level, including the modulation of transcription factors and genes directly linked to longevity-related pathways. One of the main relevant evolutionarily-conserved transcription factors modulated by astaxanthin is the forkhead box O3 gene (FOXO3), which has been recognized as a critical controller of cell fate and function. Moreover, FOXO3 is one of only two genes shown to robustly affect human longevity. Due to its tropism in the brain, ASX has recently been studied as a putative neuroprotective molecule capable of delaying or preventing brain aging in different experimental models of brain damage or neurodegenerative diseases. Astaxanthin has been observed to slow down brain aging by increasing brain-derived neurotrophic factor (BDNF) levels in the brain, attenuating oxidative damage to lipids, protein, and DNA and protecting mitochondrial functions. Emerging data now suggest that ASX can modulate Nrf2, FOXO3, Sirt1, and Klotho proteins that are linked to longevity. Together, these mechanisms provide support for a role of ASX as a potential geroneuroprotector.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.